gemtuzumab ozogamicin

CHEBI:CHEBI_756387

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
1944704
generic_name
gemtuzumab ozogamicin
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
active_ingredient_strength
5 mg/5mL
route
INTRAVENOUS
dosage_form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
marketing_category
BLA
marketing_start_date
20170907
package_marketing_start_date
20170907
labeler_name
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
manufacturer_name
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
brand_name
Mylotarg
brand_name_base
Mylotarg
product_ndc
0008-4510
application_number
BLA761060
spl_id
8323fbb8-fc24-472f-b6a7-c9bd0af1acee
active_ingredient_name
GEMTUZUMAB OZOGAMICIN
package_ndc
0008-4510-01
package_description
1 VIAL, SINGLE-DOSE in 1 CARTON (0008-4510-01) / 5 mL in 1 VIAL, SINGLE-DOSE
unii
8GZG754X6M
spl_set_id
32fd2bb2-1cfa-4250-feb8-d7956c794e05
nui
N0000175077
pharm_class_epc
CD33-directed Immunoconjugate [EPC]
pharm_class
CD33-directed Antibody Interactions [MoA]
pharm_class_moa
CD33-directed Antibody Interactions [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class